Novacyt S.A.
(“Novacyt”, the “Company” or the “Group”)
Exercise of Warrants and Issue of Equity
Paris, France and Camberley, UK – 31 January 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has received notice from Negma Group Ltd of an exercise of warrants to subscribe for, 1,679,544 new ordinary shares of €1/15 each in the capital of the Company (“Ordinary Shares”) at a price of €0.20 per share for a total subscription price of €335,908.80.
Application will be made for 1,679,544 new Ordinary Shares to be admitted to trading on AIM (“Admission”) and it is expected that Admission will become effective at 8.00 a.m. on 6 February 2020. Admission of the new Ordinary Shares to trading on Euronext is expected to occur on or before 6 February 2020.
Total Voting Rights
Following Admission, the total number of shares in the Company is 59,774,298. This figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company pursuant to Article L. 223-7 of the French Commercial Code and the Company’s Articles. The Company is not subject to the disclosure guidance and transparency rules made by the Financial Conduct Authority under Part VI of FSMA.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
For further information, please refer to www.novacyt.com or contact:
Novacyt SA
Graham Mullis, Chief Executive Officer
Anthony Dyer, Chief Financial Officer
+44 (0)1276 600081
SP Angel Corporate Finance LLP (Nominated Adviser and Broker)
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470
FTI Consulting (International)
Victoria Foster Mitchell / Mary Whittow
+44 (0)20 3727 1000
[email protected] / [email protected]
FTI Consulting (France)
Arnaud de Cheffontaines / Astrid Villette
+33 (0)147 03 69 47 / +33 (0)147 03 69 51
[email protected] / [email protected]
About Novacyt Group
The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company’s lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high quality assays and reagents worldwide. The Group directly serves oncology, microbiology, haematology and serology markets as do its global partners, which include major corporates.
END
IOESDLFAFESSESF
